120
Participants
Start Date
August 21, 2024
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2028
Human plasma derived antithrombin
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
Placebo
Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
RECRUITING
Atrium Health Wake Forest Baptist, Winston-Salem
NOT_YET_RECRUITING
University of Miami, Miami
RECRUITING
The Ohio State University, Columbus
RECRUITING
OU Health University of Oklahoma Medical Center, Oklahoma City
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
Stanford University School of Medicine, Stanford
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Duke University Medical Center, Durham
RECRUITING
University Hospital Innsbruck, Innsbruck
RECRUITING
Vienna General Hospital AKH, Medical University of Vienna, Vienna
RECRUITING
Center of Cardiovascular and Transplant Surgery, Brno
RECRUITING
Institute for Clinical and Experimental Medicine, Prague
RECRUITING
CHU de Reims, Hôpital Robert Debré, Reims
RECRUITING
CHU de Rennes, Rennes
RECRUITING
Hospital of Lithuanian university of Health sciences Kauno Klinikos, Kaunas
RECRUITING
Institute for Cardiovascular Diseases C.C. Iliescu, Bucharest
RECRUITING
University Medical Centre Ljubljana, Ljubljana
RECRUITING
Royal Papworth Hospital, Cambridge
RECRUITING
Royal Columbian Hospital, New Westminster
NOT_YET_RECRUITING
Kingston Health Sciences Centre, Kingston
NOT_YET_RECRUITING
Toronto General Hospital, Toronto
NOT_YET_RECRUITING
Montreal Heart Institute, Montreal
Lead Sponsor
Octapharma
INDUSTRY